NRIX — Nurix Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1549595 ·
Last close
$17.38
Market Cap
$1.80B
52W High
$17.85
52W Low
$14.01
ADV30
1,001,348
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Feb 2026 | 6,252,000 | — | -92,495,000 | -87,174,000 | 636,130,000 | 71,195,000 | 155,237,000 |
| Nov 2025 | 13,577,000 | — | -83,095,000 | -78,221,000 | 688,135,000 | 246,960,000 | 149,388,000 |
| Aug 2025 | 7,894,000 | — | -91,385,000 | -86,421,000 | 522,472,000 | 78,438,000 | 150,220,000 |
| May 2025 | 44,056,000 | — | -48,322,000 | -43,464,000 | 591,555,000 | 84,260,000 | 143,952,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-260,292,000
Investing CF
$-1,506,000
Financing CF
$257,144,000
CapEx
$-11,562,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.16
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,090,400,000
Inventory
—
Receivables
$19,000,000
ST Investments
$469,537,000
EBIT TTM
$-315,297,000
Pretax Income TTM
$-294,520,000
Interest Exp TTM
—
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,779,000
EBITDA
$-307,311,008
Free Cash Flow
$-145,462,624
Enterprise Value
$1,327,524,736
Total Cash
$540,732,032
Total Debt
$58,655,000
Shares Out
103,405,813
Trailing EPS
$-3.17
Book Value
$4.65
ROE
-61.4%
ROA
-31.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 83,980,000 | -285,666,000 | -264,457,000 | 688,135,000 | 149,388,000 | — | -249,465,000 |
| Nov 2024 | 54,549,000 | -213,027,000 | -193,569,000 | 669,343,000 | 142,350,000 | — | -172,584,000 |
| Nov 2023 | 76,987,000 | -155,063,000 | -143,948,000 | 355,598,000 | 155,105,000 | — | -81,365,000 |
| Nov 2022 | 38,627,000 | -183,867,000 | -180,360,000 | 416,759,000 | 113,063,000 | — | -159,807,000 |
TTM Snapshot
Revenues TTM
$41,846,000
NetIncome TTM
$-131,647,000
OpCashFlow TTM
$0
Assets (Latest)
$669,343,000
Forward EPS
$-2.86
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $1.81B | $29.93 | — |
| GLPG | Lakefront Biotherapeutics NV | $1.81B | $27.49 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.82B | $8.29 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.76B | $19.90 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.76B | $16.67 | — |
News headlines (Yahoo Finance, 1h cache)
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
2026-05-18 11:35 · Yahoo
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M
2026-05-14 20:05 · Yahoo
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance
2026-05-14 12:13 · Yahoo
How Investors Are Reacting To Nurix Therapeutics (NRIX) Securing EHA Oral Slot For BTK Degrader Data
2026-05-14 08:11 · Yahoo
Nurix Therapeutics to Participate in Upcoming Investor Conferences
2026-05-13 11:00 · Yahoo
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
2026-05-12 20:05 · Yahoo
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000
2026-05-06 21:13 · Yahoo
Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart Money
2026-04-27 14:03 · Yahoo
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
2026-04-22 11:00 · Yahoo
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
2026-04-20 00:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.